Quent Capital LLC Sells 127 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Quent Capital LLC cut its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 31.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 283 shares of the medical equipment provider’s stock after selling 127 shares during the quarter. Quent Capital LLC’s holdings in Zimmer Biomet were worth $30,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ZBH. Dunhill Financial LLC increased its stake in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the last quarter. Stonebridge Financial Group LLC bought a new position in Zimmer Biomet in the fourth quarter valued at approximately $25,000. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet in the third quarter valued at approximately $28,000. Brooklyn Investment Group bought a new position in Zimmer Biomet in the third quarter valued at approximately $35,000. Finally, R Squared Ltd bought a new position in Zimmer Biomet in the fourth quarter valued at approximately $63,000. 88.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of recent analyst reports. Barclays decreased their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday. Stifel Nicolaus lifted their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Truist Financial restated a “hold” rating and issued a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday. Raymond James cut their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, Royal Bank of Canada cut their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Price Performance

ZBH stock opened at $99.94 on Friday. The firm has a market cap of $19.89 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 1.83 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90. The company’s fifty day simple moving average is $106.67 and its 200 day simple moving average is $107.85.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the business earned $2.20 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were issued a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.96%. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.